Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Silvania Ng

Infectious Disease Cincinnati, OH Medical Doctor

NPI 1053386540 CMS profile 47261

10495 Montgomery Rd, Suite 17, Cincinnati, OH 45242

Open in the dashboard

General payments

$32,893

331 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Silvania Ng of Cincinnati, OH is reported in the CMS Open Payments database as having received $32,893 across 331 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Infectious Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $679 30
2021 General $2,948 84
2020 General $9,477 80
2019 General $19,789 137

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Silvania Ng
  • Infectious Disease median
  • Middle half of Infectious Disease
  • National median

In program year 2025, general payments to Silvania Ng were reported at $0. Among 3,905 Infectious Disease profiles paid that year, the median was $188 and the middle half received between $57 and $766.

Show as a table
Year Silvania Ng Infectious Disease median Middle half National median
2019 $19,789 $190 $60–$862 $163
2020 $9,477 $124 $32–$606 $114
2021 $2,948 $148 $38–$905 $132
2022 $679 $166 $50–$834 $149
2023 $0 $171 $57–$787 $160
2024 $0 $176 $52–$752 $164
2025 $0 $188 $57–$766 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Insmed, Inc. $15,555 43 payments
  2. Allergan Inc. $6,718 37 payments
  3. Paratek Pharmaceuticals, Inc. $4,220 39 payments
  4. AbbVie, Inc. $1,850 18 payments
  5. Gilead Sciences, Inc. $1,459 79 payments
  6. ViiV Healthcare Company $729 36 payments
  7. Merck Sharp & Dohme Corporation $612 33 payments
  8. Theratechnologies Inc. $416 19 payments
  9. Shionogi Inc $317 7 payments
  10. Nabriva Therapeutics, plc $298 2 payments
  11. Other $719 18 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $20,040 14 payments
  2. Food and Beverage $6,694 296 payments
  3. Travel and Lodging $3,218 11 payments
  4. Consulting Fee $1,800 3 payments
  5. Honoraria $880 1 payment
  6. Education $261 6 payments
Products named General payments · program years 2019–2022
  1. Arikayce $14,388 41 payments
  2. DALVANCE $5,420 29 payments
  3. NUZYRA $4,220 39 payments
  4. AVYCAZ $2,905 21 payments
  5. DOVATO $706 34 payments
  6. TROGARZO $393 17 payments
  7. Biktarvy $334 3 payments
  8. Fetroja $317 7 payments
  9. DELSTRIGO $316 19 payments
  10. DIFICID $299 12 payments
  11. Other $2,148 93 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

331 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Infectious Disease in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record